Therapy News and Research

RSS

New review analyzes appropriateness of off-pathway cancer care

Clinical oncology pathways are an important tool, helping cancer care providers and their patients to zero in on the most appropriate care plan.

30 May 2020

Scientists identify factors influencing outcomes in kidney cancer patients treated with immunotherapy

By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, Dana-Farber Cancer Institute scientists have identified several features of the tumors that influence their response to immune checkpoint inhibitor drugs.

30 May 2020

Globaldata: Cardiovascular procedures not impacted by COVID-19 as heavily as other therapy areas

The COVID-19 crisis is not impacting cardiovascular procedures as heavily as it is other therapy areas, since the majority of these procedures are essential, according to GlobalData, a leading data and analytics company. GlobalData estimates that 96.7% of cardiovascular procedures performed in the US are essential procedures.

30 May 2020

Toshiba and Shinshu University jointly develop a 'tumor-tropic liposome technology' for gene therapy

Toshiba Corporation and a team led by Professor Yozo Nakazawa at the Department of Pediatrics, Shinshu University, have together developed a “tumor-tropic liposome technology” for gene therapy. The technology uses unique, nano-sized biodegradable liposomes developed by Toshiba to accurately and efficiently deliver therapeutic genes to targeted cancer cells, and achieves safer gene delivery than viruses used as carriers.

30 May 2020

Newer treatment approaches may reduce risk of therapy-related hematologic cancers

While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches.

29 May 2020

Clinical trial shows anti-tumor responses in metastatic castration-resistant prostate cancer patients

The preliminary results of a Phase I clinical trial conducted by researchers at the Yale Cancer Center have shown that ARV-110, an androgen receptor PROTAC protein degrader, demonstrates clinical evidence of anti-tumor responses in patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed prior therapy.

29 May 2020

C-DOCTOR receives $30-million grant from NIDCR for tissue and organ regeneration research

The initiative aims to propel USC forward as the epicenter of tissue and organ regeneration research.

29 May 2020

Monoclonal antibody therapy achieves modest reduction in recurrence for patients with HER2-positive DCIS

The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) on the NRG Oncology clinical trial NSABP B-43.

29 May 2020

Adoptive T-cell therapy targeting MAGE-A4 achieves responses in patients with multiple solid tumors

The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

29 May 2020

Targeted therapy tepotinib shows durable response in NSCLC patients with METex14 skipping mutation

Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study published today in the New England Journal of Medicine and presented at the 2020 American Society of Clinical Oncology Annual Meeting ASCO20 Virtual Meeting (Abstract 9556 - Poster 322) by researchers from The University of Texas MD Anderson Cancer Center.

29 May 2020

Targeted therapy pralsetinib shows high response rates in patients with RET fusion-positive cancers

The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the international Phase I/II ARROW trial, led by researchers at The University of Texas MD Anderson Cancer Center.

29 May 2020

Addition of monoclonal antibody to trimodality therapy offers no benefit in HER2 over expressing esophageal cancer

Results of the NRG Oncology clinical trial RTOG 1010 indicated that the addition of the monoclonal antibody trastuzumab to neoadjuvant trimodality treatment did not improve disease-free survival outcomes for patient with HER2 overexpressing local and locally advanced esophageal adenocarcinoma.

29 May 2020

Study finds nitrous oxide use during labor to be safe with rare side effects

Researchers at the University of Colorado College of Nursing and the School of Medicine Department of Anesthesiology at the Anschutz Medical Campus found that the use of nitrous oxide as a pain relief option for individuals in labor is safe for newborn children and laboring individual, and converting to a different form of pain relief such as an epidural or opioid is influenced by a woman's prior birth history and other factors.

29 May 2020

Using gene therapy to help the body to make its own cancer drugs

Imagine that we could instruct our bodies to make the drugs they need themselves. The gene technology that makes this possible is called mRNA therapy, which may become a major tool in the treatment of multiple diseases.

29 May 2020

Blood test offers new opportunities to improve malarial control and elimination strategies

Plasmodium vivax is the most widespread malaria parasite worldwide, with up to two billion people at risk of infection.

29 May 2020

Chronobiological treatment can help treat insomnia

Insomnia disorder is the second-most common mental health problem and a major risk factor for depression. Cognitive behavioral therapy for insomnia (CBTi) is the treatment of choice and has successfully been provided through the Internet (ICBTI).

29 May 2020

Researchers review all clinical and research findings related to COVID-19

Due to the devastating worldwide impact of COVID-19, the illness caused by the SARS-CoV-2 virus, there has been unprecedented efforts by clinicians and researchers from around the world to quickly develop safe and effective treatments and vaccines.

29 May 2020

New tool may predict best treatment for multiple myeloma

In 1844, multiple myeloma was first treated with a rhubarb pill and an infusion of orange peel. Since then, more than 15 drugs have earned FDA approval to treat multiple myeloma and with so many options, a major question has become what cocktail and sequence is best?

29 May 2020

Scientist explore potential drugs to prevent cell resistance in different types of cancer

Cancer therapy may shrink the tumor of a patient, and the patient may feel better. But unseen on a CT scan or MR image, some of the cells are undergoing ominous changes.

29 May 2020

Combination therapy does not show superior efficacy in newly diagnosed myeloma

The combination of carfilzomib, lenalidomide, and dexamethasone (KRd) did not show superior efficacy in patients with newly diagnosed myeloma absent a high-risk disease prognosis, compared with the standard of care--bortezomib, lenalidomide, and dexamethasone (VRd).

29 May 2020

Therapy News and Research

New review analyzes appropriateness of off-pathway cancer care

Scientists identify factors influencing outcomes in kidney cancer patients treated with immunotherapy

Globaldata: Cardiovascular procedures not impacted by COVID-19 as heavily as other therapy areas

Toshiba and Shinshu University jointly develop a 'tumor-tropic liposome technology' for gene therapy

Newer treatment approaches may reduce risk of therapy-related hematologic cancers

Clinical trial shows anti-tumor responses in metastatic castration-resistant prostate cancer patients

C-DOCTOR receives $30-million grant from NIDCR for tissue and organ regeneration research

Monoclonal antibody therapy achieves modest reduction in recurrence for patients with HER2-positive DCIS

Adoptive T-cell therapy targeting MAGE-A4 achieves responses in patients with multiple solid tumors

Targeted therapy tepotinib shows durable response in NSCLC patients with METex14 skipping mutation

Targeted therapy pralsetinib shows high response rates in patients with RET fusion-positive cancers

Addition of monoclonal antibody to trimodality therapy offers no benefit in HER2 over expressing esophageal cancer

Study finds nitrous oxide use during labor to be safe with rare side effects

Using gene therapy to help the body to make its own cancer drugs

Blood test offers new opportunities to improve malarial control and elimination strategies

Chronobiological treatment can help treat insomnia

Researchers review all clinical and research findings related to COVID-19

New tool may predict best treatment for multiple myeloma

Scientist explore potential drugs to prevent cell resistance in different types of cancer

Combination therapy does not show superior efficacy in newly diagnosed myeloma

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News